期刊
CURRENT PHARMACEUTICAL DESIGN
卷 24, 期 14, 页码 1502-1517出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612824666180410091511
关键词
Alcohol induction; antioxidants; CYP2A5; CYP2A6; CYP2E1; Nrf2; reactive oxygen species; interactions; pyrazole; alcoholic liver disease; liver fibrosis; nicotine; PPARa; FGF21; LPS; TNF alpha; MAPK; HIF-1 alpha; autophagy; coumarin 7-hydroxylase
资金
- USPHS from the National Institute on Alcohol Abuse and Alcoholism [AA-018790, AA-021362, AA -020877, AA-024723]
- ABMRF/The Foundation for Alcohol Research
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA020877, R21AA021362, R01AA024723, R01AA018790] Funding Source: NIH RePORTER
Alcohol consumption causes liver diseases, designated as Alcoholic Liver Disease (ALD). Because alcohol is detoxified by alcohol dehydrogenase (ADH), a major ethanol metabolism system, the development of ALD was initially believed to be due to malnutrition caused by alcohol metabolism in liver. The discovery of the microsomal ethanol oxidizing system (MEOS) changed this dogma. Cytochrome P450 enzymes (CYP) constitute the major components of MEOS. Cytochrome P450 2E1 (CYP2E1) in MEOS is one of the major ROS generators in liver and is considered to be contributive to ALD. Our labs have been studying the relationship between CYP2E1 and ALD for many years. Recently, we found that human CYP2A6 and its mouse analog CYP2A5 are also induced by alcohol. In mice, the alcohol induction of CYP2A5 is CYP2E1-dependent. Unlike CYP2E1, CYP2A5 protects against the development of ALD. The relationship of CYP2E1, CYP2A5, and ALD is a major focus of this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据